Correspondence Dr Félix René Compen, Radboud universitair medisch centrum voor mindfulness, Postbus 9101, 6500 HB Abstract Objective: It was previously determined that group-based face-to-face Mindfulness-Based Cognitive Therapy (MBCT) and individual internet-based MBCT (eMBCT) are equally efficacious compared with treatment as usual (TAU) in reducing psychological distress. In this study, the incremental cost-utility of both interventions compared with TAU was assessed. Methods: This cost-utility study included 245 self-referred heterogeneous cancer patients with psychological distress who were randomized to MBCT, eMBCT or TAU. Healthcare costs and (informal) work-related productivity losses were assessed by interview. Outcomes were expressed in EuroQol-5D-3L utility scores and qualityadjusted life years (QALY). An economic evaluation with a time-horizon of 3 months was conducted from the societal perspective in the intention-to-treat sample. In addition, secondary explorative analyses of costs and quality of life during the 9-month follow-up were conducted based on linear extrapolation of TAU. Results: Paid work-related productivity losses and societal costs were lower in both intervention conditions compared with TAU during the 3-month intervention period. Moreover, quality of life (utility scores) improved in eMBCT versus TAU (Cohen's d: .54) and MBCT versus TAU (.53). At a willingness to pay of €20000 per QALY, the mean incremental net monetary benefit was €1916 (SD=€783) in eMBCT and €2365 (SD=€796) in MBCT versus TAU. Exploration of costs demonstrated an equal pattern of eMBCT and MBCT being superior to TAU. Quality of life at 9-month follow-up remained improved in both interventions. Conclusions: Results indicate that eMBCT and MBCT are cost-saving treatments whilst simultaneously improving quality of life for distressed cancer patients.
| BACKGROUND
Psychological distress is a negative emotional experience which impedes coping with cancer and its treatment. 1 Psychological distress is highly prevalent in cancer patients 2 and results in serious consequences such as reduced quality of life, decreased compliance with medical care, prolonged duration of hospital stay 3, 4 and increased (inadequate) healthcare use. 5 Although not all distressed cancer patients subsequently wish for psychological treatment, 6 the availability of effective treatment for psychological distress in cancer patients is required.
Psychological treatment in cancer patients yield small to medium effects in reducing psychological distress. 7 In addition to cognitive behavioural therapy, mindfulness-based interventions (MBIs) 8, 9 are increasingly offered in oncological settings. Several randomized controlled trials (RCTs) indicate that MBIs result in significant improvements of depressive and anxiety symptoms in cancer patients, e.g. [10] [11] [12] MBIs are usually offered as an eight-week, face-to-face group training. However, attending group-based MBI is not always possible for cancer patients. 13 In contrast, Internet-based interventions are easily accessible, available 24/7 when delivered asynchronously and save travelling time. 14, 15 A recent multicentre RCT in 245 selfreferred heterogeneous cancer patients with (mild) psychological distress showed that both group-based mindfulness-based cognitive therapy (MBCT) and individual internet-based MBCT (eMBCT) had a moderate effect in reducing psychological distress in comparison with treatment as usual (TAU). 11 The uncontrolled follow-up period of 9 months demonstrated consolidation of treatment effects in both interventions. 16 However, it remains unknown whether (e)MBCT provides value for money. 17 Evidence on cost-effectiveness of MBIs is focused mainly on depression. 18 A systematic review of economic evaluations of 11 third-wave cognitive behavioural interventions included 5 studies on MBIs, with two studies on MBIs in recurrent major depression and single studies on MBIs in patients with multiple sclerosis, medically unexplained symptoms or cancer. Evidence on cost-effectiveness of MBIs in these populations was deemed inconclusive. 19 Another review of economic evaluations of acceptance-and mindfulnessbased interventions reached a similar conclusions. 18 With regard to specific economic evaluations of MBIs in cancer patients, a study in 129 breast cancer patients suffering from persistent pain explored cost-effectiveness of MBCT compared with wait-list control with a time horizon of 6 months. When willingnessto-pay (WTP) was €0, the MBCT intervention was cost-effective with a probability of 85%. 20 Another study in 104 breast cancer patients compared the cost-effectiveness of mindfulness-based stress reduction (MBSR) with wait-list controls with a time horizon of 12 weeks.
MBSR was more costly ($+666) with an incremental QALY gain of +0.03 compared with wait-list controls, resulting in an ICER of $22,200/QALY. 21 Another study in 191 breast cancer patients investigated the cost-effectiveness of mindfulness-based art therapy (MBAT) compared with an active support group with a time horizon of 9 weeks. MBAT demonstrated the potential to achieve parity with the support group intervention if some intervention-related costs were reduced. 22 In short, the first studies demonstrate a tentatively positive, but inconclusive view of the economic potential of MBIs. An economic evaluation of an electronically delivered format of MBCT is yet to be conducted. The primary aim of the current study was to evaluate the cost-effectiveness of both eMBCT and MBCT compared with TAU from the societal perspective in the period from baseline (T0) to post-treatment (T1). The secondary aim was to explore costs and quality of life during the 9 month-follow-up (12-month time horizon) based on a linear extrapolation of TAU. The study was registered on Clinicaltrials.gov (NCT02138513), reported following CONSORT guidelines. 23 A protocol paper was published in advance. 24 All participants provided written informed consent prior to enrolment.
| Interventions

| Face-to-face MBCT
The MBCT protocol 9 was followed except for slight tailoring to the cancer patient. MBCT consisted of eight weekly 2.5h group sessions guided by a therapist, a six-hour one-day silent retreat and daily home practice assignments of about 45 minutes. All therapists in this study were accredited in concordance with the UK Mindfulness-Based Teacher Trainer Network Good Practice Guidelines.
| eMBCT
The eMBCT was identical to MBCT in terms of content but was delivered individually and included weekly asynchronous written interaction with a therapist over email. For more information, we refer to our other work. 11, 15 2.3.1 | Treatment as usual Treatment as usual (TAU) consisted of all healthcare patients wished to receive. There were no restrictions on healthcare utilization during the study period, except not participating in MBIs.
| Measures
| Healthcare costs
The Trimbos/iMTA questionnaire for Costs associated with Psychiatric illness (TiC-P) 25 was used to collect information on direct healthcare use and paid and informal work-related productivity losses. The TiC-P is a self-report instrument, but in the current study the TiC-P was administered by the researchers in an interview format. The recommended time-horizon for determining healthcare costs by TiC-P of three months was used. 25 Direct healthcare costs were calculated by multiplying volumes of care by standardized unit prices indexed using Dutch national price indices to the 2016 price level 26 (see Table S1 in the Supporting Information). Prescription medication costs were retrieved from the Dutch national tariff list (https://www.medicijnkosten.nl). Societal costs were calculated as the sum of medical and formal and informal productivity loss costs for T1, T1+T2, and T1+T2+(T3*2), reaching a time horizon of 12 months (9 months post-treatment).
| Indirect costspaid and informal workrelated productivity losses
Indirect costs due to paid work-related productivity losses included absenteeism and presenteeism costs. Absenteeism costs were calculated by multiplying the number of hours patients were absent from their job by the gross wage per hour according to the Dutch guideline for health economic evaluations. 27 Presenteeism costs were calculated by multiplying estimated number of work hours lost by gross wage per hour. Indirect costs related to paid work-related productivity losses were calculated according to the Friction Cost method. 28 Once patients met the friction period criterium of >85 sick days at a specific time point (starting count at baseline) no additional indirect costs due to work were calculated during the rest of the study period. Indirect costs related to productivity loss in informal work were also included. 27 The recall period for paid and informal work-related productivity losses was 4 weeks (as per default), which was proportionately extrapolated from 4 weeks to 3 months to match the recall period of the healthcare use questionnaire. Dutch national price indices were used to index healthcare and productivity costs to the 2016 price level 26 and costs were presented in Euros.
| Intervention costs
Additionally, intervention costs were €299.00 per person for patients participating in the MBCT and €331.16 per person for patients participating in eMBCT (see Table S2 ). In MBCT, travel and parking related costs were calculated on an individual basis. 27 Intervention development costs were regarded as sunk costs and were therefore disregarded because they would not need to be repeated if the intervention were adopted on a broader scale. 29 
| Quality of life
To measure the health-related quality of life (QoL) of cancer patients, a validated health-related QoL instrument was used: the EuroQol-5D-3L (EQ-5D). 30, 31 We chose to use a generic QoL measure as opposed to a cancer-specific measure such as the EORTC QLQ since we were interested in measuring utilities. 32 The EQ-5D index is obtained by applying predetermined weights to the five domains. This index gives a societal-based global utility score of the participant's health status on a scale between-.33 (worse than death) and 1 (perfect health).
From the utility scores at T0 and T1 QALYs were calculated for each patient using the Area Under the Curve (AUC) method: ((EQ 5D T0 + EQ 5D T1) /2) * (3/12) using the Dutch index tariff. 31 
| Linear extrapolation
One way to deal with extrapolation of a cost pattern is to assume a linear relationship between costs and volume within some relevant range. Within that relevant range, the total cost varies linearly with volume, at least approximately. In terms of somatic care, patients followed clinical routine with which we did not intervene and which would remain similar after TAU. With regard to psychological care it is known that psychological distress levels are associated with healthcare consumption 5 and these did not change in patients receiving TAU only. 11 Therefore, the T1 measurement in TAU was linearly extrapolated up to 12 months. In addition, the net monetary benefit (NMB) was determined:
| Analyses
NMB=(effect E of intervention expressed in QALY * WTP)costs C for intervention. If the incremental NMB (ΔE * WTP -ΔC) is > 0, the intervention is considered to be cost-effective compared with an alternative. For the exact WTP is unknown, results of regression analyses with the NMB as dependent variable were subsequently used to obtain a cost-effectiveness acceptability curve (CEAC) by plotting 1-P/ 2 against different levels of WTP (0, 20000, 40000, 60000, 80000) for a QALY where P is the P value from the coefficient on the treatment dummy variable in the regression analyses. 34 3 | RESULTS
| Sample characteristics
In total, 245 self-referred heterogeneous cancer patients with psychological distress were randomly assigned to eMBCT (n=90), MBCT (n=77) or TAU (n=78) (See Figure 1) . The three conditions did not differ in terms of baseline demographic or clinical characteristics (see Table 1 ). Intervention dropout was significantly higher in the eMBCT than in the MBCT group: (χ 2 (1, n=167)=3.92, P = .047). The three conditions did not differ in employment status at baseline, although there were differences at a descriptive level Of the patients who had a job at baseline, relatively more patients met the friction period criterium in both interventions compared with TAU, although this difference was not significant (χ 2 (2, n=245)=5.25, P = .072) (see Table S3 ). During the intervention period, a total of n=24 (33%) in eMBCT used a form of mental healthcare compared with n=18 (29%) in MBCT and n=20 (32%) in TAU. This difference was not significant between conditions. Study dropout (number of missing measurements at end of treatment) did not differ between conditions. Study dropouts did not differ from study completers in healthcare costs, informal work costs or EQ-5D utility scores at baseline. Study dropouts did have marginally signifi- 
| Cost-utility: 3 month time-horizon
| Costs
Direct healthcare costs did not differ significantly between the two intervention conditions and TAU (see Table 2 ). Costs associated with 
| Quality of life
When QoL was expressed in EuroQol-5D-3L utility scores, patients in the eMBCT and MBCT conditions reported significantly higher QoL at T1 than patients in TAU ( F (2,198)=8.02, P < .001, see Table 2) 
| Cost-utility
The cost-utility planes (Figure 2 Figure S1 ).
| Exploration of costs and quality of life during the 9 month-follow-up
| Costs
Healthcare costs were significantly lower in eMBCT and MBCT compared with TAU in (P = .035 and P = .048, respectively). Paid work- TABLE 2 (Aggregated) costs per category in Euros and EQ-5D utility scores per condition and per measurement with TAU costs at T2 and T3 extrapolated from T1. All reported P values concern the P value of the three-armed comparison 
| Quality of life
Patients in both interventions maintained the increased QoL over the follow-up period with no significant differences between eMBCT and MBCT.
| CONCLUSIONS
The aim of the current study was to evaluate the cost-utility of both eMBCT and MBCT compared with TAU from the societal perspective in the period from baseline (T0) to post-treatment (T1) and to explore development of costs and quality of life during the 9 month-follow-up results in the period from baseline to 9 month-follow-up (T3). atively more patients without a job were lost-to-follow up. The results must therefore be interpreted with caution and future studies should preferably stratify for employment status.
Several psychosocial interventions have previously been demonstrated to represent good value for money in cancer care. 35 A review of 11 cost-effectiveness studies of psychosocial interventions in cancer care indicate cost-effectiveness at different WTP thresholds, but that more research is necessary and that more research should be performed encompassing potential important cost drivers from a societal perspective. 36 The current results are partly in line with previous findings on costeffectiveness of MBIs for cancer patients [20] [21] [22] although it must be noted that there are considerable differences between the studies in terms of population, intervention, measures and analysis perspective.
Moreover, the current sample was self-referred.
| Study limitations
The most important limitation is lack of follow-up for TAU. As cancer patients might recover spontaneously from psychological distress, it might not be appropriate to assume that costs and QoL remained stable over time. However, our sample consisted of cancer patients on average 3.5 years post diagnosis, rendering them less likely to recover spontaneously. 37 Moreover, our period of "watchful waiting" took well over the usual period of "watchful waiting" in other studies, e.g. 38 Therefore, we considered it justified to extrapolate TAU from T1.
| Clinical implications
These results imply that offering Internet-based MBCT in clinical practice improves accessibility of psycho-oncological care whilst saving societal costs, without compromising intervention efficacy.
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